Theranostic and Molecular Classification of Breast Cancer

Cornejo, Kristine M.; Kandil, Dina; Khan, Ashraf; Cosar, Ediz F.

doi:10.5858/arpa.2012-0442-ra

Cited by 41 publications

(32 citation statements)

References 174 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…For NETs, the development of biomathematically weighted scoring systems will facilitate the introduction of a risk probability ( 52 ) analysis and allow for the improvement of prognostic and predictive information, thereby aiding clinical decision making ( 29,53 ). An alternative possibility is that interface of bloodbased transcriptional information relating to the proliferative regulation of tumor growth metastasis and metabolism will likely provide information that is synergistic with neuroendocrine cell function ( 29 ).…”

Section: Discussionmentioning

confidence: 99%

The Clinical Utility of a Novel Blood-Based Multi-Transcriptome Assay for the Diagnosis of Neuroendocrine Tumors of the Gastrointestinal Tract

Modlin

Kidd

Bodei³

et al. 2015

American Journal of Gastroenterology

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

The Clinical Utility of a Novel Blood-Based Multi-Transcriptome Assay for the Diagnosis of Neuroendocrine Tumors of the Gastrointestinal Tract

Modlin

Kidd

Bodei³

et al. 2015

American Journal of Gastroenterology

View full text Add to dashboard Cite

show abstract

“…Algorithmic analyses, using the results of these assays as well as other patient information (if used), can then be performed and are typically reported as a numeric score(s) or as a probability (Eastman et al 2012) that can provide additional prognostic and predictive information, further aiding clinical management (Cornejo et al 2014). The strengths of MAAAs are the incorporation of multiple informative data points as well as these are typically undertaken by a single dedicated facility (Lee & Hall 2009).…”

Section: Discussionmentioning

confidence: 99%

A multianalyte PCR blood test outperforms single analyte ELISAs (chromogranin A, pancreastatin, neurokinin A) for neuroendocrine tumor detection

Modlin

Drozdov

Alaimo

et al. 2014

Endocrine-Related Cancer

View full text Add to dashboard Cite

A critical requirement in neuroendocrine tumor (NET) management is a sensitive, specific and reproducible blood biomarker test. We evaluated a PCR-based 51 transcript signature (NETest) and compared it to chromogranin A (CgA), pancreastatin (PST) and neurokinin A (NKA). The multigene signature was evaluated in two groups: i) a validation set of 40 NETs and controls and ii) a prospectively collected group of NETs (nZ41, 61% small intestinal, 50% metastatic, 44% currently treated and 41 age-sex matched controls). Samples were analyzed by a two-step PCR (51 marker genes) protocol and ELISAs for CgA, PST and NKA. Sensitivity comparisons included c 2 , non-parametric measurements, ROC curves and predictive feature importance (PFAI) analyses. NETest identified 38 of 41 NETs. Performance metrics were: sensitivity 92.8%, specificity 92.8%, positive predictive value 92.8% and negative predictive value 92.8%. Single analyte ELISA metrics were: CgA 76, 59, 65, and 71%; PST 63, 56, 59, and 61% and NKA 39, 93, 84, and 60%. The AUCs (ROC analysis) were: NETest: 0.96G0.025, CgA: 0.67G0.06, PST 0.56G0.06, NKA: 0.66G0.06. NETest significantly outperformed single analyte tests (area differences: 0.284-0.403, Z-statistic 4.85-5.9, P!0.0001). PFAI analysis determined NETest had most value (69%) in diagnosis (CgA (13%), PST (9%), and NKA (9%)). Test data were consistent with the validation set (NETest O95% sensitivity and specificity, AUC Z0.98 vs single analytes: 59-67% sensitivity, AUCs: 0.58-0.63). The NETest is significantly more sensitive and efficient (O93%) than single analyte assays (CgA, PST or NKA) in NET diagnosis. Blood-based multigene analytic measurement will facilitate early detection of disease recurrence and can predict therapeutic efficacy.

show abstract

“…Breast cancer is the leading cause of cancer-related mortality in women worldwide. 1 It is a heterogeneous disease at the molecularegenetic and clinical levels, resulting in variable responses to existing treatment modalities. 2 Recent gene expression profiling studies have subclassified breast cancer into at least 4 molecular subtypes including at least luminal A and B, human epidermal growth factor receptor (HER2)-positive, and triple-negative breast cancer (TNBC; estrogen receptor [ER], progesterone receptor [PR], HER2-negative disease).…”

Section: Introductionmentioning

confidence: 99%

Predictive Biomarker Profiling of > 6000 Breast Cancer Patients Shows Heterogeneity in TNBC, With Treatment Implications

Millis

Gatalica

Winkler

et al. 2015

Clinical Breast Cancer

View full text Add to dashboard Cite

Multi-platform molecular profiling identifies subgroups of TNBC with different biomarker profiles, suggesting numerous potentially targetable alterations in TNBC. TNBC is further characterized by different gene mutations and proliferative activity relative to AR expression, highlighting a need for comprehensive pathologic examination with potential to develop different, individualized treatment options.

show abstract

Theranostic and Molecular Classification of Breast Cancer

Cited by 41 publications

References 174 publications

The Clinical Utility of a Novel Blood-Based Multi-Transcriptome Assay for the Diagnosis of Neuroendocrine Tumors of the Gastrointestinal Tract

The Clinical Utility of a Novel Blood-Based Multi-Transcriptome Assay for the Diagnosis of Neuroendocrine Tumors of the Gastrointestinal Tract

A multianalyte PCR blood test outperforms single analyte ELISAs (chromogranin A, pancreastatin, neurokinin A) for neuroendocrine tumor detection

Predictive Biomarker Profiling of > 6000 Breast Cancer Patients Shows Heterogeneity in TNBC, With Treatment Implications

Contact Info

Product

Resources

About